A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT...
Timely expansion enhances capacity amidst rapid sales growth ANN ARBOR, MI / ACCESSWIRE / June 4, 2024 / Zomedica Corp....
NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create...
HOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its...
Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an...
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to...
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing...
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced...
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular...
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched...
Scope of the SESHAT Project at Pioneering Hospital, Part of the Catalan Health Institute, Includes Deployment of up to 1,000...
In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved...
BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic...
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE...
BIRMINGHAM, United Kingdom--(BUSINESS WIRE)--As part of the MedTech Innovation Expo, the leading trade show in the medical device design and...
OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced...
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for...
Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use authorization of serial, novel monoclonal antibodies...
Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and AmylyxAppointment intended to accelerate the...
REDWOOD CITY, CA / ACCESSWIRE / May 30, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to...